Loomis Sayles & Co. L P Has $20.56 Million Stock Position in Rxo Inc $RXO

Loomis Sayles & Co. L P trimmed its stake in shares of Rxo Inc (NYSE:RXO) by 2.3% in the second quarter, according to the company in its most recent filing with the SEC. The firm owned 1,307,867 shares of the company’s stock after selling 31,188 shares during the quarter. Loomis Sayles & Co. L P owned about 0.80% of RXO worth $20,560,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. AlphaQuest LLC acquired a new position in shares of RXO in the second quarter valued at approximately $29,000. Geneos Wealth Management Inc. purchased a new position in RXO during the 1st quarter worth $30,000. CWM LLC grew its stake in RXO by 234.4% in the 1st quarter. CWM LLC now owns 1,876 shares of the company’s stock valued at $36,000 after purchasing an additional 1,315 shares during the period. Thurston Springer Miller Herd & Titak Inc. raised its holdings in shares of RXO by 25.1% in the 2nd quarter. Thurston Springer Miller Herd & Titak Inc. now owns 3,433 shares of the company’s stock worth $54,000 after purchasing an additional 688 shares during the period. Finally, Nisa Investment Advisors LLC lifted its position in shares of RXO by 34.1% during the 2nd quarter. Nisa Investment Advisors LLC now owns 4,576 shares of the company’s stock valued at $72,000 after buying an additional 1,163 shares during the last quarter. 92.73% of the stock is currently owned by institutional investors and hedge funds.

RXO Trading Up 1.6%

NYSE RXO opened at $13.22 on Monday. The stock’s 50 day moving average is $15.21 and its 200 day moving average is $15.77. The firm has a market capitalization of $2.17 billion, a PE ratio of -30.74 and a beta of 1.74. The company has a quick ratio of 1.32, a current ratio of 1.32 and a debt-to-equity ratio of 0.24. Rxo Inc has a twelve month low of $10.43 and a twelve month high of $30.40.

RXO (NYSE:RXO) last issued its quarterly earnings results on Thursday, November 6th. The company reported $0.01 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.02). RXO had a negative net margin of 1.25% and a positive return on equity of 0.88%. The business had revenue of $1.42 billion for the quarter, compared to analysts’ expectations of $1.44 billion. During the same period last year, the business earned $0.05 earnings per share. The company’s revenue was up 34.6% on a year-over-year basis. Research analysts forecast that Rxo Inc will post 0.31 earnings per share for the current fiscal year.

Insider Buying and Selling

In other RXO news, Director Thomas A. Szlosek bought 20,308 shares of the business’s stock in a transaction on Friday, November 7th. The shares were acquired at an average cost of $12.37 per share, for a total transaction of $251,209.96. Following the purchase, the director owned 36,508 shares in the company, valued at approximately $451,603.96. This trade represents a 125.36% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Andrew M. Wilkerson acquired 7,775 shares of RXO stock in a transaction that occurred on Monday, November 10th. The stock was acquired at an average price of $12.88 per share, with a total value of $100,142.00. Following the completion of the acquisition, the chief executive officer directly owned 7,775 shares in the company, valued at $100,142. This represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have bought a total of 40,250 shares of company stock worth $488,875 in the last quarter. Corporate insiders own 1.48% of the company’s stock.

Wall Street Analyst Weigh In

RXO has been the topic of a number of analyst reports. UBS Group lowered their target price on shares of RXO from $17.00 to $15.00 and set a “neutral” rating on the stock in a report on Friday, November 7th. Wolfe Research raised shares of RXO from an “underperform” rating to a “peer perform” rating in a research note on Friday, November 14th. Benchmark reissued a “hold” rating on shares of RXO in a report on Wednesday, October 22nd. The Goldman Sachs Group lowered their price target on shares of RXO from $17.00 to $15.00 and set a “neutral” rating for the company in a research note on Thursday, October 9th. Finally, Truist Financial cut their target price on shares of RXO from $22.00 to $20.00 and set a “buy” rating on the stock in a report on Friday, November 7th. Four analysts have rated the stock with a Buy rating, eleven have given a Hold rating and four have assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $16.69.

About RXO

RXO, Inc provides full truckload freight transportation brokering services. It also offers brokered services for managed transportation, last mile, and freight forwarding. The company was incorporated in 2022 and is based in Charlotte, North Carolina.